Follow-up after Direct-acting Antiviral Treatment for Chronic Hepatitis C Virus Infection: Most Patients Are Followed Appropriately
Open Access
- 1 October 2021
- journal article
- research article
- Published by Japanese Society of Internal Medicine in Internal Medicine
- Vol. 60 (19), 3061-3070
- https://doi.org/10.2169/internalmedicine.6591-20
Abstract
Objective Chronic hepatitis C virus (HCV) infection carries a residual risk of hepatocarcinogenesis even after viral elimination, so appropriate follow-up is necessary. The present study investigated the current hospital visits and hepatocarcinogenesis status of patients who received daclatasvir plus asunaprevir treatment (DCV+ASV) to determine whether or not appropriate follow-up was being performed. Methods We retrospectively analyzed hepatocarcinogenesis, the overall survival, and the length of hospital visits in 442 patients who applied for the medical expense subsidy system for viral hepatitis and received DCV+ASV treatment in Gunma Prefecture between October 2014 and December 2015. This also included 61 patients who had a history of hepatocellular carcinoma (HCC). Results Among 442 patients, 388 achieved a sustained viral response (SVR) by DCV+ASV therapy (87.8%), and 95.9% achieved an SVR if additional treatment was included. HCC was found in 75 cases (17.0%). A history of HCC, the FIB-4 index and the treatment effect SVR were determined to be factors affecting the incidence of HCC. Regarding the follow-up rate, 89.9% of patients continued to regularly visit the hospital after 5 years of treatment. However, patients ≤60 years old had significantly lower persistence rates than older patients. The persistence rate of hospital visits to the same institution was 67.7% over a 5-year period, which was significantly better in small and medium-sized institutions than in large, specialized institutions (71.7% vs. 63.9%, p=0.039). Conclusion Patients with direct-acting antiviral treatment generally received adequate follow-up, but younger patients had a slightly higher rate of follow-up interruption and were considered to need support.Keywords
This publication has 32 references indexed in Scilit:
- Daclatasvir plus asunaprevir for chronic HCV genotype 1b infectionJournal of Hepatology, 2014
- Investigation of the freely available easy-to-use software ‘EZR’ for medical statisticsBone Marrow Transplantation, 2012
- Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment optionsJournal of Hepatology, 2012
- Cancer preventive effect of pegylated interferon α-2b plus ribavirin in a real-life clinical setting in Japan: PERFECT interim analysisHepatology Research, 2011
- The history and current state of drug abuse in JapanAnnals of the New York Academy of Sciences, 2011
- Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: Incidence and survival in hepatitis C patients with advanced fibrosisJournal of Hepatology, 2010
- Changing Trends in Hepatitis C Infection over the Past 50 Years in JapanIntervirology, 2010
- The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosisGut, 2009
- Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfectionJournal of Hepatology, 2006
- Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: A long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysisJournal of Hepatology, 1999